Dantari is a clinical stage biotechnology company based in Thousand Oaks, California. They specialize in the development of targeted high-capacity drug conjugates (T-HDC) for the treatment of cancer and other serious diseases. Their proprietary platform technology optimizes the performance of these drug conjugates, leveraging validated targets and a range of therapeutic payload options. Dantari's focus is on creating rapid advancements in therapies, particularly across the blood-brain barrier, to provide meaningful medical improvement for patients.